This week’s Psychedelic Titan is Christopher Moreau, CEO of Algernon Pharmaceuticals. Algernon Pharmaceuticals is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and COVID-19.
What’s this article series about? Psychedelic Titans is a get-to-know-you-style blog series interviewing some of the psychedelic industry’s most influential and impactful individuals.
When did you first become involved in the psychedelic industry and why?
In February 2021, Algernon Pharmaceuticals, the Company I am the CEO of, decided to open a new research program for DMT and stroke.
Do you, or have you taken, psychedelic substances?
Not relevant
What’s your favourite psychedelic compound?
NA
Do your parents/family members know what you’re doing?
Yes
Have you had an experience with mental health/chronic pain?
Yes
What’s your vision of the industry in 20 years?
I believe that there will be a dramatic change in the loosening of laws restricting psychedelic drug access and use and that those changes will be for the betterment of mankind.
What are your biggest worries for the industry?
Restrictions that are in place globally that make scientific investigation of psychedelics unnecessarily difficult and expensive for companies and researchers.
Who are your heroes?
Krishnamurti
If you could create a psychedelic to do anything you wanted, what would it do?
Heal the brain and make people smarter
We’d like to thank Christopher Moreau for being a part of the Psychedelic Titans series. Stay tuned for more profiles on leaders in the psychedelic industry.
Would you like to participate in this series? Fill out this form and we’ll follow up with a review of your application.
